Press Releases 2013
 
Press Releases 2012
 
Press Releases 2011
 
Press Releases 2010
 
Press Releases 2009
 
Press Releases 2008
 
Press Releases 2007
 
Press Releases 2006
 
Press Releases 2005
 
Press Releases 2004
 
Press Releases 2003
 
 
12.17.12
Ironwood and Forest Announce U.S. Availability of LINZESS(TM) (Linaclotide)

12.06.12
Protagonist and Ironwood Expand Peptide Drug Discovery Collaboration

11.28.12
Constella (linaclotide) approved in Europe for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults

11.09.12
Ironwood Pharmaceuticals to Present at the Credit Suisse 2012 Healthcare Conference

11.01.12
Ironwood Pharmaceuticals to Host Webinar on Accounting Treatment for LINZESS(TM) (linaclotide)

10.23.12
Ironwood and AstraZeneca Announce Linaclotide Collaboration in China

10.16.12
Ironwood Pharmaceuticals Provides Third Quarter 2012 Investor Update

10.10.12
Ironwood Pharmaceuticals to Host Third Quarter 2012 Investor Update Call

09.21.12
Linaclotide Receives Positive CHMP Opinion for the Treatment of IBS-C

09.12.12
Ironwood Pharmaceuticals to Present at the UBS Global Life Sciences Conference

09.06.12
Ironwood Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

08.30.12
Ironwood and Forest Announce FDA Approval of Linzess(TM) (Linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

08.30.12
Ironwood and Forest to Host Conference Call to Discuss FDA Approval of Linzess(TM) (linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

07.17.12
Ironwood Pharmaceuticals Provides Second Quarter 2012 Investor Update

07.10.12
Ironwood Pharmaceuticals to Host Second Quarter 2012 Investor Update Call

05.29.12
Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences

05.14.12
Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week 2012

05.08.12
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2012 Health Care Conference

05.01.12
Ironwood Pharmaceuticals Provides First Quarter 2012 Investor Update

04.24.12
Ironwood Pharmaceuticals to Host First Quarter 2012 Investor Update Call

04.23.12
Ironwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012

02.28.12
Ironwood Pharmaceuticals Provides Fourth Quarter 2011 Investor Update

02.27.12
Ironwood Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference

02.21.12
Ironwood Pharmaceuticals to Host Fourth Quarter 2011 Investor Update Call

02.13.12
Ironwood Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock

02.09.12
Ironwood Pharmaceuticals Prices Public Offering of Common Stock

02.08.12
Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock

02.08.12
Ironwood Announces FDA Advisory Committee Meeting Will Not Be Scheduled in Connection with New Drug Application for Linaclotide

01.04.12
Ironwood Pharmaceuticals and Bionomics Announce Collaboration, Research, and License Agreement
- Companies to Collaborate on Central Nervous System Disorder Opportunity

01.03.12
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

 

Lisa Buffington
VP, Corporate Communications
617.374.5103
 
         
Copyright © 2013, Ironwood Pharmaceuticals, Inc.All Rights Reserved|Privacy Policy|Terms of Service|Site Design